The HT-29 colorectal cancer cell line, which has previously been shown to be resistant to EGFR signalling blockade by cetuximab, due to a downstream mutation in BRAF25, was used to avoid therapeutic effect of cetuximab by EGFR blockade. Here, EGFR is linked to colorectal cancer.